Acurx Pharmaceuticals, Inc. (ACXP)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q1-2026 | — | ||
| 10-KLatest | FY-2025 | — | ||
| 10-Q | Q3-2025 | — | ||
| 10-Q | Q2-2025 | 8-K (2025-05-13) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-03-18) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2024-11-13) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-08-09) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-05-15) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-03-18) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2023-11-14) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-08-14) · 99.1 | ||
| 10-Q | Q2-2023 | — |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Balance Sheets | ||
| Condensed Interim Balance Sheets | — |
|
| Balance Sheets (P) | ||
| Condensed Interim Balance Sheets (P) | — |
|
| Condensed Interim Statements of Operations | — |
|
| Statements of Operations | ||
| Condensed Interim Statements of Changes In Shareholders' Equity (unaudited) | — |
|
| Statements of Changes In Shareholders' Equity | ||
| Condensed Interim Statements of Changes In Shareholders' Equity (unaudited) (P) | — |
|
| Statements of Changes In Shareholders' Equity (P) | ||
| Condensed Interim Statements of Cash Flows | — |
|
| Statements of Cash Flows | ||
| Statements of Cash Flows (P) | — |
|
| Notes | ||
| Accounts Payable and Accrued Expenses | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management and Strategy Disclosure | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Issuance of Equity Interests | ||
| Nature of Operations | ||
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Share-based Compensation | ||
| Share-based Payments To Vendors | ||
| Subsequent Events | ||
| Summary of Significant Accounting Policies | ||